DSNKY (Daiichinkyo Co) LT-Debt-to-Total-Asset : 0.03 (As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Daiichinkyo Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Daiichinkyo Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.03.

Daiichinkyo Co's long-term debt to total assets ratio declined from Dec. 2023 (0.03) to Dec. 2024 (0.03). It may suggest that Daiichinkyo Co is progressively becoming less dependent on debt to grow their business.

Daiichinkyo Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Daiichinkyo Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co LT-Debt-to-Total-Asset Chart

Daiichinkyo Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.09

0.08

0.06

0.04

0.03

Daiichinkyo Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.03	-	0.03	0.03

Daiichinkyo Co LT-Debt-to-Total-Asset Calculation

Daiichinkyo Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	676.244	/	23102.172
	=	0.03

Daiichinkyo Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	656.818	/	22388.113
	=	0.03

Daiichinkyo Co (OTCPK:DSNKY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Daiichinkyo Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

DSKYF:USA 4568:Mexico 4568:Japan D4S:Germany

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.